Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Bogner

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Nature Immunology|August 10, 2023
Fibrosis induced by resident macrophages has divergent roles in pancreas inflammatory injury and PDACJohn M Baer, Chong Zuo, Liang-I Kang, et al.
Cancer Discovery|September 27, 2022
Stromal Reprogramming by FAK Inhibition Overcomes Radiation Resistance to Allow for Immune Priming and Response to Checkpoint BlockadeVarintra E Lander, Jad I Belle, Natalie L Kingston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2022
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion StudyAndrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2023
Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion StudyAndrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Nature Immunology|August 10, 2023
Fibrosis induced by resident macrophages has divergent roles in pancreas inflammatory injury and PDACJohn M Baer, Chong Zuo, Liang-I Kang, et al.
Cancer Discovery|September 27, 2022
Stromal Reprogramming by FAK Inhibition Overcomes Radiation Resistance to Allow for Immune Priming and Response to Checkpoint BlockadeVarintra E Lander, Jad I Belle, Natalie L Kingston, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 13, 2022
Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion StudyAndrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 14, 2023
Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion StudyAndrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, et al.
Pageof 5